Clinical Research Directory
Browse clinical research sites, groups, and studies.
Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder
Sponsor: The University of Texas Health Science Center, Houston
Summary
The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.
Official title: Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder: A Pilot Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-07-25
Completion Date
2027-01-30
Last Updated
2025-09-05
Healthy Volunteers
No
Conditions
Interventions
SUVO
Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
TAU
Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
Locations (1)
The University of Texas Health Science Center at Houston
Houston, Texas, United States